RxDoctor Payments Data

Daniel Destefano

Family · Alexandria, VANPI 1497488423

Payments from drug & device makers

$2,786in general payments, 2019–2025

Across 118 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$596
  • Viiv Healthcare Company$519
  • Novo Nordisk$428
  • AstraZeneca$222
  • Lilly USA, LLC$116
  • Medtronic$111
  • plus $793 from 16 others

What the payments were for

  • Food & beverage$2,772100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,786 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$10,672
Medicare patients
71
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala25$103,687
DovatoDolutegravir Sodium/Lamivudine32$96,223
MounjaroTirzepatide14$15,838
EntrestoSacubitril/Valsartan15$13,299
EliquisApixaban14$12,202
JardianceEmpagliflozin16$10,114
XareltoRivaroxaban12$8,816
Albuterol Sulfate HfaAlbuterol Sulfate26$554
Gabapentin46$458
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$391
Metoprolol Succinate49$335
Ibuprofen20$279
Atorvastatin Calcium46$273
Rosuvastatin Calcium31$258
Famotidine17$240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$596$103,68725 claims
Viiv Healthcare CompanyDovato$519$96,22332 claims
Lilly USA, LLCMounjaro$116$15,83814 claims
PfizerEliquis$88$12,20214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Alexandria

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →